Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study

Stopped AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.

Conditions

• Rheumatoid Arthritis

Interventions

• DRUG: Fostamatinib
• DRUG: Adalimumab
• DRUG: Placebo of Fostamatinib
• DRUG: Placebo of Adalimumab

Sponsor

AstraZeneca